-

Kashiv BioSciences to Present at the 44th Annual J.P. Morgan Healthcare Conference

PISCATAWAY, N.J.--(BUSINESS WIRE)--Kashiv BioSciences, LLC (“Kashiv”), a vertically integrated biopharmaceutical company, today announced that Dr. Sandeep Athalye, Global Chief Executive Officer, and Dr. Paras Vasanani, Head of Business Development, will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, California, on Wednesday, January 14, 2026, at 11:00 a.m. PST.

44th Annual J.P. Morgan Healthcare Conference – Kashiv BioSciences Company Presentation
Date: Wednesday, January 14, 2026
Time: 11:00 - 11:25 a.m. PST
Location: Golden Gate Conference Room – The Westin St. Francis Hotel, San Francisco, California

About Kashiv BioSciences:
Kashiv BioSciences, LLC is a vertically integrated biopharmaceutical company with numerous commercial and advanced clinical-stage assets and is among the few U.S.-based companies to both manufacture and receive marketing authorization for multiple biosimilars. Kashiv BioSciences, LLC in the USA, and its subsidiaries in India (together “Kashiv BioSciences”) operate together with robust infrastructure and highly skilled teams that provide global R&D, clinical, manufacturing, regulatory, and IP capabilities. We believe our people, partners, and shared purpose fuel our work to advance patient care and access to important medicines. For more information, visit www.kashivbiosciences.com and follow us on LinkedIn.

Contacts

For further information or queries please contact:
Dr. Paras Vasanani
Head – Business Development
paras.vasanani@kashivbio.com

Heena Dhedhi
Head – Corporate Communications
heena.dhedhi@kashivbio.com

Industry:

Kashiv BioSciences, LLC

Release Versions
EnglishSpanishGermanFrenchItalianDutch

Contacts

For further information or queries please contact:
Dr. Paras Vasanani
Head – Business Development
paras.vasanani@kashivbio.com

Heena Dhedhi
Head – Corporate Communications
heena.dhedhi@kashivbio.com

More News From Kashiv BioSciences, LLC

Kashiv BioSciences Announces Validation and Acceptance of Market Authorization Application by Health Canada for ADL-018, a Proposed Biosimilar to XOLAIR® (omalizumab)

PISCATAWAY, N.J.--(BUSINESS WIRE)--Kashiv BioSciences, LLC (“Kashiv”), a vertically integrated biopharmaceutical company, today announced that Health Canada has validated and accepted the marketing authorization application (MAA) for ADL-018, the Company’s proposed biosimilar for XOLAIR® (omalizumab). Omalizumab, a humanized monoclonal antibody that targets free IgE, is indicated for the treatment of moderate to severe persistent asthma (6 years and older patients), chronic rhinosinusitis with...

Kashiv BioSciences Agrees to Be Acquired by Amneal Pharmaceuticals to Create a Fully Integrated Global Biosimilar Leader

PISCATAWAY, N.J.--(BUSINESS WIRE)--Kashiv BioSciences, LLC (“Kashiv”), today announced that it has entered into a definitive agreement to be acquired by Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal”). The transaction is subject to approval by Amneal shareholders, receipt of regulatory approvals and satisfaction of customary closing conditions and is expected to close in the second half of 2026. This acquisition combines Kashiv’s extensive expertise in the development and manufacturing o...

Kashiv BioSciences Strengthens Executive Leadership with New Chief Operating Officer and Senior Vice President of Regulatory Affairs

PISCATAWAY, N.J.--(BUSINESS WIRE)--Kashiv BioSciences, LLC (“Kashiv”), a vertically integrated biopharmaceutical company, today announced the appointment of Viet Nguyen as Chief Operating Officer and Arlene Wolny as Senior Vice President of Regulatory Affairs. Both leaders will be based in Piscataway, New Jersey. Viet Nguyen has over two decades of leadership experience, with deep expertise in building high-performing teams, scaling complex operations, and driving commercial readiness across mu...
Back to Newsroom